How safe are new biologic agents in treating patients with hepatitis and rheumatic diseases?
Incidence of hepatitis B virus reactivation in patients with resolved infection on immunosuppressive therapy for rheumatic disease: a multicentre, prospective, observational study in Japan
Background Although the reactivation of hepatitis B virus (HBV) is recognised as a serious complication in patients with rheumatic disease (RD) receiving immunosuppressive drugs (ISDs), the incidence and risk factors for reactivation remain controversial. Objectives To investigate the incidence and…
While biologic use did not significantly increase the risk of Hepatitis B reactivation, age above 68 conferred over 3 times the risk. Methotrexate use reduced the risk by 60%, while steroid use increased it more than twice.